1 week Ago By Defense World Staff
Norges Bank bought a new stake in CeriBell ( NASDAQ:CBLL – Free Report ) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 16,316 shares of the company’s stock, valued at approximately $422,000. Several other institutional investors and hedge funds have also bought and sold shares of CBLL.
PNC Financial Services Group Inc. purchased a new stake in shares of CeriBell during the 4th quarter valued at about $47,000. Corebridge Financial Inc.
purchased a new stake in shares of CeriBell in the 4th quarter worth $158,000. Rhumbline Advisers bought a new stake in CeriBell during the fourth quarter valued at about $320,000. Bank of New York Mellon Corp purchased a new stake in CeriBell in the fourth quarter worth about $628,000.
Finally, JPMorgan Chase & Co. bought a new position in shares of CeriBell in the fourth quarter worth about $880,000. Wall Street Analyst Weigh In A number of brokerages recently issued reports on CBLL.
LADENBURG THALM/SH SH began coverage on CeriBell in a research note on Friday, April 4th. They set a “buy” rating and a $32.00 price objective for the company.
Canaccord Genuity Group reiterated a “buy” rating and issued a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.
com, the stock has an average rating of “Buy” and an average price target of $32.50. CeriBell Stock Performance Shares of CBLL opened at $15.
00 on Friday. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.
75. The company’s 50 day simple moving average is $21.04.
CeriBell ( NASDAQ:CBLL – Get Free Report ) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.
32) by ($0.08). The firm had revenue of $18.
53 million for the quarter, compared to analysts’ expectations of $17.55 million. On average, equities analysts expect that CeriBell will post -2.
46 EPS for the current year. CeriBell Company Profile ( Free Report ) We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Articles Five stocks we like better than CeriBell Manufacturing Stocks Investing Robinhood Strategies Could Be a Game-Changer for Young Investors Low PE Growth Stocks: Unlocking Investment Opportunities Are These 3 Retail Stocks Oversold or Really in Trouble? There Are Different Types of Stock To Invest In IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead Want to see what other hedge funds are holding CBLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CeriBell ( NASDAQ:CBLL – Free Report ). Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.
com's FREE daily email newsletter ..
